Sanofi (NYSE:SNY) reportedly sued Mylan (NSDQ:MYL) today, accusing the company of illegally suppressing competition to the EpiPen device. The lawsuit filed in a New Jersey federal court alleges that Mylan’s conduct has cost Sanofi hundreds of millions of dollars in sales for its rival allergy treatment, Auvi-Q.
Canonsburg, Penn.-based Mylan has found itself at the center of the pharmaceutical industry’s pricing problem over the past year. In August, reports revealed that the company has hiked the price of its device more than 500% since it acquired the EpiPen from Merck (NYSE:MRK) in 2007. Since then, CEO Heather Bresch has endured questioning by lawmakers and the company has been probed by the Federal Trade Commission.
Get the full story at our sister site, Drug Delivery Business News.
The post Sanofi levels antitrust suit against Mylan over EpiPen device appeared first on MassDevice.
from MassDevice http://ift.tt/2pawaLk
Cap comentari:
Publica un comentari a l'entrada